AUTL's Quality Score rose 3 points on Mon, Oct 26, to 0. Its volume went quiet (2 chart checks started). 1 more reason, for Pro members.
Follow AUTL's trial news. Pro members can get an alert when Autolus Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 73% over five years while the S&P 500 rose 78%.
“This improvement in gross margin was primarily driven by a reduction in manufacturing cost per batch”
2 more reasons why AUTL lags the market, from its filings, with the company's words, the timeline, and its peers, for Pro members.
| Since its 2024 high | Down 79% |
| Latest filing | S-3, Sep 14 |
4 more reasons behind AUTL's 0, for Pro members.
Tue Nov 10: American College of Rheumatology…Industry event · date confirmed.
After its last 4 reports it closed -2.5% on average, higher 1 of 4 times.
The company says its cash lasts into Q2 2028 (8-K, Aug 11).
No shelf registration or at-the-market program on file in the last three years.
An officer, Cintia Piccina, sold 6,713 shares on Sep 2.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below AverageTrending up, 2 of 14 chart checks firingWhat the Quality Score means
Well below its recent run. AUTL scores 0 today, against a median of 4 over its last 20 recorded sessions.
AUTL is #143 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 143 |
Reports Tue Nov 10, before the open (in 15 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“Net revenues were primarily driven by increasing product demand both within existing treatment centers and expansion into new centers, supplemented by contribution from UK sales in the second quarter of launch in this market.”
AUTL's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.
| Measure | Figure |
|---|---|
| AUCATZYL net product revenue | $140M to $150M |
“This improvement in gross margin was primarily driven by a reduction in manufacturing cost per batch, reflecting increased volumes and the ongoing operational efficiency initiatives, and lower inventory reserves and write-offs compared to the same period in the prior year.”
From its results filing (SEC filing · Aug 11)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 11, 2026 | -1.4% | +12.6% | +10.1% |
| May 14, 2026 | -8.8% | -7.0% | -5.3% |
| Mar 27, 2026 | -6.2% | -6.2% | +9.3% |
One insider sold $16K across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
AUTL scores 0 today, which Breakaway calls Below Average. It is #143 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 73% over five years while the S&P 500 rose 78%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
AUTL scores 0 today, which Breakaway calls Below Average (0 to 5). That is #143 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AUTL's 0.
One insider sold $16K across 1 filing in the last 6 months. No open-market buys on record. The newest is Cintia Piccina, U.S. CCO & Country Gen Manager, who sold $16K on Sep 2.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.